News

for MaaT013 to Treat Acute Graft-versus-Host Disease.

using its BioChaperone® platform.

Funded by NIAID.

To accelerate clinical trials of its precision cancer vaccines.

They joined us !

They joined us !

for Broad-Spectrum “Universal” Influenza Vaccine in Japan.

to initiate its feasibility clinical study in Post Cardiac Arrest Syndrome.

They joined us!

They joined us !

AdoShell® Islets is an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy and AdoGel® Sema a technology enabling the sustained release of semaglutide.

securing up to €1 million from ACT Venture Partners.

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline.

as a member of its Supervisory Board.

sur le Forfait Innovation pour le traitement des patients atteints de glioblastome récurrent.

Eric Vacaresse succeeds Christian Deleuze

They joined us !

They joined us !

Preliminary data from the First-in-human ODYSSEY study show that ABD-3001 was well tolerated

In his new role, he will oversee Adocia’s operations and help accelerate its development and growth

They joined us !

The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health.

Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

Phase II clinical trial for ALS patients with drug candidate NX210c

Total liquid Ventilation takes another step towards becoming a clinical reality

from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine etteurs

Against Pediatric Cancer Cell Lines

Definitive Agreement to be Acquired.

to demonstrate the efficient expansion of human adipose-derived stem cells (hADSC) in stirred-tank bioreactors.

They joined us !

Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS).

for PKM-01, for local treatment of gout flares, directly by a Phase 2 trial.

They joined Lyonbiopole !

au poste de Président.

With cancellation of the preferential subscription rights through
an international private placement reserved for specialized or strategic investors.

featuring a collaboration between Promega and FDA.

She brings over 25 years of experience in vaccine development.

With xista science ventures, Foundation Fournier-Majoie and Noshaq.

Chloé Hodonou is the new Director of Research and Development at Aptys.

MagIA diagnostics is pleased to announce that Mr. Philippe Jacon will be joining the Board of MagIA diagnostics.

They joined us !

They joined us.

They expand their collaborative efforts to accelerate life science innovation worldwide.

They joined Lyonbiopole’s membership

of innovative drug candidate for neurodegenerative diseases

with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023.

 for Clinical Development of MaaT033 as part of the France 2030 Plan

In collaboration with GSK.

They joined Lyonbiopole’s membership !

in Acute Graft-versus-Host Disease with MaaT013

from AIFA for extended production capacity in HPAPIs and Steroids.

Combining expertise in the research of new phages and phage endolysins that could be applied to human health

to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

For Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research

Medical device industry executive with 30+ years expertise brings wealth of experience in product development and commercial launches to support Carthera’s future growth

Impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes, a first for a non-drug active substance

The Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies.

New study by Promega and WuXi AppTec demonstrates novel chemical probes from DELs

aiming to improve overall survival in patients undergoing hematopoietic stem cell transplantation

ADMIR designs, develops and manufactures an active infrared spectroscopic imaging device and develops AI image processing software.

It’s Highlighting Clinical Benefit of MaaT013 in aGvHD

MTIG is a coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based product…

High-throughput MEA-capable organs-on-chip

For EXO-NET exosome isolation and nucleic acid purification solutions

Evidence of cross-protection against multiple SARS-CoV-2 variants of concern observed in hamster challenge model

and Obtains Commitment from Investors to Provide 10 Million Euros in Financing.

to the Board and Executive Team.

➡ Merger approved with large majority by the shareholders of both companies
➡ New governance structure implemented
➡ Ambition to create a global leader in extended phage therapies to target
antimicrobial resistant pathogenic bacteria

to support Company’ Innovation Capabilities

ETISENSE (Lyon) and the EUROPEAN RESEARCH BIOLOGY CENTER (ERBC Group) announce a collaboration to develop and validate the DECRO telemetry solution for marmosets, a new world primate with several advantages in non-clinical studies.

From business angel groups, family offices, BPI, the Auvergne Rhône Alpes region and the ANR.

Gérard Soula is reappointed as Chairman of the Board of Directors ;
Olivier Soula’s primary near-term objective is to sign a partnership on M1Pram and renegotiate agreements with Company’s main lenders.

Laboratoires Pomega developq a patented Anti Inflammatory Drug.

HuntX Pharma develops drugs to prevent the onset and development of genetic neurological diseases.

Following Positive End of Phase 2 Meeting with FDA.

Published in Lancet Oncology.

demonstrates that SARS-CoV-2 awakens ancient retroviral genes and the expression of proinflammatory HERV-W envelope protein in COVID-19 patients.

Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease.

To Initiate Named Patient Program for KIMOZO® (temozolomide) in European Countries

France is set to become a global leader in using AI to diagnose and
treat diseases through €33 million Owkin-led AI project

For the development and characterization of T-cell redirecting therapies

Specialized in R&D of new anti-infective drugs, Nosopharm is currently open to industrial and academic partnerships to pursue development of innovative pipeline to fight antibiotic resistance.

for OVX836, its Broad-Spectrum Influenza Vaccine.

to accelerate the development of its drug candidate in Parkinson’s disease

ReACT Therapeutics aims of restoring the efficacy of cancer treatments and improving the quality of care for patients in therapeutic failure.

AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the Alps incorporated in March 2023 with the objective of developing a new class of anti-infective biotherapeutics.

PrediSurge develops predictive software solutions for cardiovascular interventions.

Healabs designs and develops Digital Therapeutic solutions.

This system is used for treatment of recurrent glioblastoma

Manitty is not just a startup, it’s a game-changer in the world of healthcare and remote patient monitoring.

 In Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A major technological advance for research on complex neurological diseases and potential treatments

It’s outlining Path Forwardfor Investigational New Drug Application for MaaT013 in Patients with Acute Graft-verus-Host Disease

from its main shareholder Xerys Invest  

and Licensing Option with XOMA

Highlights Key Expected Milestones in 2023

 from the European Commission for for Treatment of Adrenoleukodystrophy

led by Sofinnova Partners and co-led by Intermediate Capital Group.

Lyonbiopôle wish you a happy new year 2023 !

Bio Elpida Acquisition Brings GMP Fill and Finish Capacity to Polyplus.

for BioChaperone® Lispro with Partner Tonghua Dongbao.

for a novel immuno-oncology antibody program  

presented at the ECTRIMS 2022 Congress in Amsterdam, confirms synergistic neuroprotective potential of temelimab in MS

Phase 2 Study of Temelimab at ECTRIMS 2022

in cell and gene therapy GMP manufacturing